Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
Habib Bennaceur, Senior Vice President of Rare Disease Unit at Novo Nordisk, shared a post on LinkedIn:
“For people living with haemophilia, life still involves making trade-offs each and every day.
Working with the community, we hear about the burdens people carry beyond the condition itself – including the toll of treatment administration, the planning that goes around it and balancing protection with ease, practicality and ultimately, overall quality of life.
Haemophilia is estimated to affect over one million worldwide, with over 60,000 people identified in Europe.
Novo is committed to supporting this community by bringing forwards innovation that allows people with haemophilia to live with as few limitations as possible and empowering them to be involved in decisions about their care to ensure it reflects their individual needs and goals.
That ambition is grounded in more than 100 years of experience in chronic disease and over four decades in haemophilia.
Today is a milestone moment for our teams across Europe and around the world as we move one step closer to bringing forwards our innovation and lasting health for people living with haemophlia.”
Other posts featuring Habib Bennaceur on Hemostasis Today.
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics
-
Nov 14, 2026, 23:33Alexandros Makis: Exploring Vascular Mechanisms and Therapeutic Targets in β-Thalassemia
-
Nov 14, 2026, 23:32Kalyan Roy: Asundexian Approval Marks a Milestone in Targeted Anticoagulation
-
Nov 14, 2026, 23:32Julia Pitcher: Strengthening Legislative Efforts for the Sickle Cell and Thalassemia Community
-
Nov 14, 2026, 23:31Sidi Mohamed El Amine Benlazar: The Role of Cytoreductive Therapy in MPN-Associated Splanchnic Vein Thrombosis
-
Nov 14, 2026, 23:24Roxana González: Pathogenesis of Vascular Disease in Behcet’s Syndrome